USP22 and breast carcinoma: Both genetic and pharmacological USP22 inhibition largely reduced the breast cancer stem cell pool through down-regulating integrin b1, also known as CD29, a cell surface glycoprotein that is critical in almost every step of cancer progression, including cancer initiation, proliferation, local invasion, and metastatic colonization of the new tissue 18, 19.